MilliporeSigma Introduces IsoBag™ for Faster and Easier Transfer of Contact and Settle Plates

Billerica, Massachusetts, March 21, 2016 – The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, today announced introduced the...

21 Mar 2016 | Billerica, Massachusetts, United States of America
  • Prepacked gamma-irradiated plates streamline environmental monitoring workflows
  • Save time, reduce costs by eliminating need to decontaminate plate bags
  • Mount to Alpha port of isolators, keeping plates readily available
  • Designed for environmental monitoring in isolators and critical cleanrooms

Billerica, Massachusetts, March 21, 2016 – The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, today announced introduced the IsoBag™ for faster, easier and more convenient transfer of contact and settle plates to production isolators.

The new IsoBag™ offers a more streamlined alternative for environmental monitoring, and helps make workflows more efficient, productive and flexible. In traditional environmental monitoring workflows, single-bagged plates are decontaminated and stored in the isolator. Limited space in the isolator allows storage of only a small supply of ready-to-use plates. When this supply runs out, workflows are interrupted for additional decontamination cycles. The new IsoBag™ increases operation up-time by eliminating these decontamination cycles and allowing for an uninterrupted workflow.

“An uninterrupted workflow means improved productivity for our environmental monitoring customers,” said Theresa S. Creasey, head of Applied Solutions Strategic Marketing and Innovation at MilliporeSigma. “We understand how precious time and lab space are to our customers. Our new IsoBag™ is a great example of our continued focus on the development of high-impact innovations.”

The complete product is gamma-irradiated for immediate use and includes sterile bags for safe transport of used plates.

The IsoBag™ extends MilliporeSigma’s comprehensive portfolio of products specifically designed for environmental monitoring in isolators and critical cleanrooms. All plates are produced in cleanrooms and are available with four neutralizers for inactivation of a wide range of disinfectants and inhibiting residues. The plates are designed for long shelf life and room temperature stability and meet European and U.S. pharmacopeia recommendations.

Downloads

For more information, contact Karen Tiano

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Related News

Press Releases

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum ...

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin ...

2018/11/19

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement